BICRA

BRD4-interacting chromatin-remodeling complex-associated protein · Q9NZM4 · BICRA on Sugi Atlas →

0 patent compounds predicted against BICRA, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to BICRA by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD PHASE3COMPLETED
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients PHASE3UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma PHASE1/PHASE2RECRUITING
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma PHASE2RECRUITING
Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma PHASE1/PHASE2WITHDRAWN
LRAs United as a Novel Anti-HIV Strategy. PHASE1/PHASE2COMPLETED
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab PHASE1/PHASE2RECRUITING
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activity of SYHA1801 Monotherapy in Patients With Advanced Solid Tumors PHASE1UNKNOWN
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies PHASE1RECRUITING
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load PHASE1COMPLETED
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma EARLY_PHASE1RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Expanded Access for Bromodomain and Extra-Terminal (BET) Inhibitor nanNO_LONGER_AVAILABLE
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
Long Non-coding RNAs and Their Role on Epigenome as Diagnostic Markers in Childhood Acute Lymphoblastic Leukemia of T Cells. nanUNKNOWN
Precision High-Intensity Training Through Epigenetics (PHITE) nanCOMPLETED
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population nanCOMPLETED
Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System nanCOMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia nanCOMPLETED
Investigation of the Genetic and Environmental Causes of Autism: a Multi-Center Study nanNOT_YET_RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants. nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a BICRA binder may also engage these)

ProteinNameSimilarity
F8VPZ9 1.000 F8VPZ9 →
Q14863 0.981 Q14863 →
Q64028 0.980 Q64028 →
P78364 0.979 P78364 →
Q07916 0.977 Q07916 →
Q9QWH1 0.977 Q9QWH1 →
Q8IXK0 0.974 Q8IXK0 →
A5D7F6 0.968 A5D7F6 →
P31367 0.968 P31367 →
O88873 0.968 O88873 →
Q8CHP6 0.967 Q8CHP6 →
Q8VCB2 0.967 Q8VCB2 →
Q6T264 0.967 Q6T264 →
Q92585 0.966 Q92585 →
Q8BJI4 0.966 Q8BJI4 →
Q9UKD1 0.966 Q9UKD1 →
Q2VPU4 0.966 Q2VPU4 →
Q96JK9 0.966 Q96JK9 →
Q9HAP2 0.965 Q9HAP2 →
Q8QHL5 0.965 Q8QHL5 →
O89090 0.965 O89090 →
Q8N9N5 0.965 Q8N9N5 →
Q8NDX5 0.965 Q8NDX5 →
Q9HCM7 0.965 Q9HCM7 →
Q08E26 0.965 Q08E26 →
Q7Z3K3 0.965 Q7Z3K3 →
E9Q1P8 0.964 E9Q1P8 →
Q91X84 0.964 Q91X84 →
A2A9T0 0.964 A2A9T0 →
Q8VHG2 0.964 Q8VHG2 →